Association of Interleukin-32 and Interleukin-34 with Cardiovascular Disease and Short-Term Mortality in COVID-19
Authors:
- Christoph C. KaufmannCKChristoph C. Kaufmann
- Amro AhmedAAAmro Ahmed
- Marie MuthspielMMMarie Muthspiel
- Isabella RostockiIRIsabella Rostocki
- Edita PogranEdita Pogran
- David ZweikerDavid Zweiker
- Achim Leo BurgerABAchim Leo Burger
- Bernhard JägerBJBernhard Jäger
- Gabriele AicherGAGabriele Aicher
- Alexander O. SpielAlexander O. Spiel
- Florian Vafai-TabriziFVFlorian Vafai-Tabrizi
- Michael GschwantlerMGMichael Gschwantler
Open Access
- 27 January 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (3) , 975
Abstract
Background: Excess cardiovascular (CV) morbidity and mortality has been observed in patients with COVID-19. Both interleukin-32 (IL-32) and interleukin-34 (IL-34) have been hypothesized to contribute to CV involvement in COVID-19. Methods: This prospective, observational study of patients with laboratory-confirmed COVID-19 infection was conducted from 6 June to 22 December 2020 in a tertiary care hospital in Vienna, Austria. IL-32 and IL-34 levels on admission were collected and tested for their association with CV disease and short-term mortality in patients with COVID-19. CV disease was defined by the presence of coronary artery disease, heart failure, stroke or atrial fibrillation and patients were stratified by CV disease burden. Results: A total of 245 eligible patients with COVID-19 were included, of whom 37 (15.1%) reached the primary endpoint of 28-day mortality. Of the total sample, 161 had no CV disease (65.7%), 69 had one or two CV diseases (28.2%) and 15 patients had ≥three CV diseases (6.1%). Median levels of IL-32 and IL-34 at admission were comparable across the three groups of CV disease burden. IL-32 and IL-34 failed to predict mortality upon both univariable and multivariable Cox regression analysis. The two CV disease groups, however, had a significantly higher risk of mortality within 28 days (one or two CV diseases: crude HR 4.085 (95% CI, 1.913–8.725), p < 0.001 and ≥three CV diseases: crude HR 13.173 (95% CI, 5.425–31.985), p < 0.001). This association persisted for those with ≥three CV diseases after adjustment for age, gender and CV risk factors (adjusted HR 3.942 (95% CI, 1.288–12.068), p = 0.016). Conclusion: In our study population of hospitalized patients with COVID-19, IL-32 and IL-34 did not show any associations with CV disease or 28-day mortality in the context of COVID-19. Patients with multiple CV diseases, however, had a significantly increased risk of short-term mortality.Keywords
Funding Information
- Bürgermeisterfond der Stadt Wien (COVID052)
- Association for the Promotion of Research on Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB) (COVID052)
- Ludwig Boltzmann Cluster for CV Research (COVID052)
This publication has 41 references indexed in Scilit:
- The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like DiseaseAutoimmunity Reviews, 2020
- Covid-19 — Navigating the UnchartedNew England Journal of Medicine, 2020
- Inflamm-ageing: the role of inflammation in age-dependent cardiovascular diseaseEuropean Heart Journal, 2020
- Interleukin-32 increases in coronary arteries and plasma from patients with coronary artery diseaseClinica Chimica Acta, 2019
- Increased Serum Interleukin-34 Levels Are Related to the Presence and Severity of Cardiac Dysfunction in Patients With Ischemic CardiomyopathyFrontiers in Physiology, 2018
- Prognostic Significance of Interleukin‐34 (IL‐34) in Patients With Chronic Heart Failure With or Without Renal InsufficiencyJournal of the American Heart Association, 2017
- IL-32 promoter SNP rs4786370 predisposes to modified lipoprotein profiles in patients with rheumatoid arthritisScientific Reports, 2017
- Activation of the Interleukin-34 Inflammatory Pathway in Response to Influenza A Virus InfectionThe American Journal of the Medical Sciences, 2015
- IL-34 Is Associated with Obesity, Chronic Inflammation, and Insulin ResistanceThe Journal of Clinical Endocrinology & Metabolism, 2014
- IL-32 Promotes AngiogenesisThe Journal of Immunology, 2014